224P Immunological dynamics in triple-negative breast cancer: Peripheral immune responses to neoadjuvant therapy
Year: 2024
Type: article
Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. In the KEYNOTE-522 trial (KN522), pembrolizumab plus neoadjuvant chemotherapy (nChT) in early TNBC improved pathological complete response (pCR) rates and event-free survival. However, its effect on peripheral blood immune responses remains unclear. This study aims to assess the impact of this association on immune populations, disease outcomes, and treatment toxicities.
Source: Immuno-Oncology Technology
Authors: R.A. Santos, F. Syeda, A. Paiva, N. Castelo-Branco, G. Sousa, T.V. Cunha Pereira, P.R. Santos
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374972